Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10x Genomics, Inc. reports developments in single cell and spatial biology, including financial results, product launches and collaborations tied to its research platforms. The company sells integrated instruments, consumables and software used by academic, translational and biopharmaceutical researchers to analyze biological systems at single-cell and spatial resolution.
Recurring updates cover platforms such as Chromium, Visium, Xenium and Atera; consumables demand; spatial whole-transcriptome analysis; research collaborations and data-generation initiatives; conference presentations; and management commentary on revenue, cash resources and outlook. Company news also reflects applications in oncology, immunology, neuroscience and other disease research areas.
10x Genomics (TXG) reported Q4 and full year 2024 financial results, showing revenue declines and continued operating losses. Q4 revenue decreased 10% to $165.0 million, while full-year revenue fell 1% to $610.8 million. The company's gross margin improved to 67% in Q4 and 68% for the full year.
Operating expenses decreased 6% to $160.8 million in Q4, with an operating loss of $49.8 million. For the full year, operating loss improved to $194.6 million from $265.3 million in 2023. The company ended 2024 with $393.4 million in cash and marketable securities.
Looking ahead, 10x Genomics provided 2025 revenue guidance of $610-630 million, projecting 0-3% growth. The company expects double-digit growth in both Chromium reactions and spatial revenue at the midpoint of guidance.
Chan Zuckerberg Initiative (CZI) has launched the Billion Cells Project, collaborating with 10x Genomics and Ultima Genomics to create an unprecedented one billion cell dataset for advancing AI in biology. The project aims to enhance understanding of cellular behavior and gene function through large-scale data generation.
The initiative will utilize 10x Genomics' Chromium GEM-X technology for single-cell analysis and Ultima Genomics' UG 100™ platform for high-throughput sequencing. The dataset will include organisms such as mouse, zebrafish, and primary human cell models, focusing on gene regulation and function across organisms.
CZI plans to make all results open source and freely available to scientists worldwide. The project will leverage CZI's computing system, one of the largest dedicated to nonprofit life sciences research, to train new virtual cell models and derive insights from the vast dataset.
10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, has announced it will release its fourth quarter and full year 2024 financial results after market close on February 12, 2025. The company will hold a conference call and webcast for analysts and investors at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.
The financial results will be available on the company's website before the conference call. Investors can access the live webcast through the 'Investors' section of 10x Genomics' website, where it will remain available for replay for at least 45 days following the event.
10x Genomics (TXG) has announced preliminary, unaudited results for Q4 and full year 2024. The company reported Q4 2024 revenue of ~$165.0 million, showing 9% sequential growth but a 10% year-over-year decrease. Full-year 2024 revenue reached ~$610.8 million, representing a 1% decrease from 2023.
Q4 breakdown shows Instruments revenue at $24.4 million (28% sequential growth, -37% YoY), Consumables revenue at $133.5 million (6% sequential growth, -5% YoY), and Services revenue at $7.1 million (12% sequential growth, +35% YoY). The company's cumulative instrument installations exceeded 7,000 units, including over 5,800 Chromium, 800 Visium, and 400 Xenium instruments. Cash position stood at approximately $393 million as of December 31, 2024.
10x Genomics (Nasdaq: TXG), a pioneer in single cell and spatial biology, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team is scheduled to present on Monday, January 13, at 7:30 a.m. Pacific Time.
The presentation will take the format of a fireside chat and will be accessible via live webcast through the 'Investors' section of 10x Genomics' website. For those unable to attend live, the webcast recording will remain available for replay for a minimum of 30 days following the event.
Bruker (BRKR) faces a permanent injunction in Delaware's U.S. District Court regarding its GeoMx products, following a patent infringement lawsuit by 10x Genomics. The Court will enter the injunction in January 2025, prohibiting Bruker from making, selling, or offering GeoMx Digital Spatial Profiler products in the United States.
The Court affirmed the $31 million damages from the November 2023 jury verdict, plus supplemental damages and interest. Notably, existing GeoMx users who installed instruments before November 18, 2023, can continue purchasing reagents for ongoing research. The jury found that the GeoMx products willfully infringed seven patents licensed to 10x Genomics by Prognosys.
10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, announced its management team will participate in a fireside chat at the Wolfe Research 2024 Healthcare Conference.
The event will take place on Tuesday, November 19, at 1:00 p.m. Eastern Time. Interested parties can access a live webcast of the chat on the Investors section of the company's website. The webcast will be archived and available for replay for at least 45 days after the event.
French TechBio startup Cure51 has selected 10x Genomics' Visium HD technology for analyzing tumor samples from exceptional cancer survivors. The initiative aims to study over 1,000 tumor samples across 40 countries in collaboration with more than 50 medical institutions over the next 18 months. Cure51 will use Visium HD's single cell-scale resolution capabilities to build the first proprietary multi-omics database of exceptional cancer survivors, focusing on understanding survival mechanisms for new therapeutic approaches. The company recently raised €15 million in Seed funding from Sofinnova, LifeX and Hitachi Ventures.
10x Genomics (TXG) reported Q3 2024 financial results with revenue of $151.7 million, representing a 1% decrease from the previous year. The company faced challenges due to sales restructuring disruption and cautious customer spending. Gross margin improved to 70% from 62% year-over-year, while operating loss decreased to $41.5 million from $94.8 million. Net loss was $35.8 million. The company launched several new products including GEM-X Flex and Chromium Xo. Due to persistent market challenges, 10x Genomics revised its full-year 2024 revenue guidance to $595-605 million, down from previous $640-660 million range.
10x Genomics has launched two new Chromium products to make single cell analysis more accessible and affordable. The GEM-X Flex and GEM-X Universal Multiplex offer improved performance, workflow, and cost-effectiveness. GEM-X Flex enables profiling of up to 2.5 million cells per run at a cost as low as $0.01 per cell, with compatibility for various sample types including FFPE samples. It requires as low as 25,000 cells per sample, a four-fold improvement in sample recovery.
The GEM-X Universal Multiplex allows on-chip multiplexing of four independent samples, up to 5,000 cells per sample, for approximately $560 per sample. This simplifies the workflow and reduces hands-on time. Both products aim to democratize single cell analysis by lowering costs per cell, sample, experiment, and project.